

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>CREDIT SUISSE FIRST BOSTON/</u>			2. Date of Event Requiring Statement (Month/Day/Year) 03/10/2004		3. Issuer Name and Ticker or Trading Symbol <u>XYTE THERAPIES INC [ XCYT ]</u>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____			5. If Amendment, Date of Original Filed (Month/Day/Year)	
ELEVEN MADISON AVENUE							
(Street)	(City)	(State)	(Zip)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			
NEW YORK NY 10010							

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Convertible Promissory Note	03/16/2004 <sup>(10)</sup>	03/16/2004	Common Stock	10,664	9.625	I	See Footnote <sup>(1)(2)</sup>
Series A Convertible Preferred Stock	03/16/2004 <sup>(11)</sup>	03/16/2004	Common Stock	478,466	5.225	I	See Footnote <sup>(1)(3)</sup>
Series B Convertible Preferred Stock	03/16/2004 <sup>(11)</sup>	03/16/2004	Common Stock	99,172	6.05	I	See Footnote <sup>(1)(4)</sup>
Series C Convertible Preferred Stock	03/16/2004 <sup>(11)</sup>	03/16/2004	Common Stock	207,805	9.185	I	See Footnote <sup>(1)(5)</sup>
Series D Convertible Preferred Stock	03/16/2004 <sup>(11)</sup>	03/16/2004	Common Stock	58,861	15.29	I	See Footnote <sup>(1)(6)</sup>
Series E Convertible Preferred Stock	03/16/2004 <sup>(11)</sup>	03/16/2004	Common Stock	64,741	15.29	I	See Footnote <sup>(1)(7)</sup>
Series F Convertible Preferred Stock	03/16/2004 <sup>(11)</sup>	03/16/2004	Common Stock	660	15.29	I	See Footnote <sup>(1)(8)</sup>
Common Stock Warrants (right to buy)	03/16/2004 <sup>(12)</sup>	03/16/2004 <sup>(13)</sup>	Common Stock	42,196	0.055	I	See Footnote <sup>(1)(9)</sup>

**Explanation of Responses:**

1. See Attachment
2. See Attachment
3. See Attachment
4. See Attachment
5. See Attachment
6. See Attachment
7. See Attachment
8. See Attachment
9. See Attachment
10. See Attachment
11. See Attachment
12. See Attachment
13. See Attachment

/s/ Ivy Dodes, on behalf of Credit Suisse First Boston business unit      03/10/2004

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

